The in-vitro activity of FK-037, a new broad spectrum injectable cephalosporin.
The in-vitro activity of the parenteral cephem FK-037 was compared to those of cefpirome, ceftazidime, cefuroxime, cefixime, amoxycillin and co-amoxiclav. Against the Enterobacteriaceae FK-037 was generally > or = 16-fold more active than cefuroxime and two- to four-fold more active than ceftazidime and similar in activity to cefpirome. Pseudomonas aeruginosa displayed similar susceptibilities to ceftazidime and FK-037 (MIC90 4 and 8 mg/L respectively). Methicillin-resistant Staphylococcus aureus were inhibited by < or = 4 mg/L of FK-037. The MIC of FK-037 for 90% of Streptococcus pneumoniae was 0.5 mg/L. Haemophilus influenzae and Moraxella catarrhalis were inhibited by < or = 2 mg/L FK-037.
Wise
R
R
Department of Microbiology, Dudley Road Hospital, Birmingham, UK.
Andrews
J M
JM
Thornber
D
D
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D004355:Drug Stability; D006801:Humans; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000494:pharmacology
D000900:Anti-Bacterial Agents; C079769:cefoselis; D015296:Ceftizoxime; D001618:beta-Lactamases